260 related articles for article (PubMed ID: 26891723)
1. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
[TBL] [Abstract][Full Text] [Related]
2. Dual-specificity phosphatase 14 (DUSP14/MKP6) negatively regulates TCR signaling by inhibiting TAB1 activation.
Yang CY; Li JP; Chiu LL; Lan JL; Chen DY; Chuang HC; Huang CY; Tan TH
J Immunol; 2014 Feb; 192(4):1547-57. PubMed ID: 24403530
[TBL] [Abstract][Full Text] [Related]
3. Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
Li L; Chen W; Zhu Y; Wang X; Jiang DS; Huang F; Wang L; Xiang F; Qin W; Wang Q; Zhang R; Zhu X; Li H; Chen X
Hypertension; 2014 Jul; 64(1):94-102. PubMed ID: 24777975
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.
Wang S; Yan ZZ; Yang X; An S; Zhang K; Qi Y; Zheng J; Ji YX; Wang PX; Fang C; Zhu XY; Shen LJ; Yan FJ; Bao R; Tian S; She ZG; Tang YD
Hepatology; 2018 Apr; 67(4):1320-1338. PubMed ID: 29077210
[TBL] [Abstract][Full Text] [Related]
5. Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload.
Li WM; Zhao YF; Zhu GF; Peng WH; Zhu MY; Yu XJ; Chen W; Xu DC; Xu YW
Clin Sci (Lond); 2017 Jan; 131(2):141-154. PubMed ID: 27702885
[TBL] [Abstract][Full Text] [Related]
6. Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
Zhao J; Jiang X; Liu J; Ye P; Jiang L; Chen M; Xia J
J Am Heart Assoc; 2021 Feb; 10(4):e014311. PubMed ID: 33522247
[TBL] [Abstract][Full Text] [Related]
7. The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor- and interleukin-1-induced nuclear factor-κB activation by dephosphorylating the protein kinase TAK1.
Zheng H; Li Q; Chen R; Zhang J; Ran Y; He X; Li S; Shu HB
J Biol Chem; 2013 Jan; 288(2):819-25. PubMed ID: 23229544
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan ameliorates pressure overload-induced cardiac remodeling through inhibition of TAK1/p38 signaling in mice.
Wu L; Mei L; Chong L; Huang Y; Li Y; Chu M; Yang X
Life Sci; 2016 Jan; 145():121-6. PubMed ID: 26706286
[TBL] [Abstract][Full Text] [Related]
9. DUSP14 knockout accelerates cardiac ischemia reperfusion (IR) injury through activating NF-κB and MAPKs signaling pathways modulated by ROS generation.
Lin B; Xu J; Feng DG; Wang F; Wang JX; Zhao H
Biochem Biophys Res Commun; 2018 Jun; 501(1):24-32. PubMed ID: 29660332
[TBL] [Abstract][Full Text] [Related]
10. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
[TBL] [Abstract][Full Text] [Related]
11. TRAF2-mediated Lys63-linked ubiquitination of DUSP14/MKP6 is essential for its phosphatase activity.
Yang CY; Chiu LL; Tan TH
Cell Signal; 2016 Jan; 28(1):145-51. PubMed ID: 26521044
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
[TBL] [Abstract][Full Text] [Related]
13. Novel role of mitochondrial GTPases 1 in pathological cardiac hypertrophy.
Xu D; Zhao Y; Weng X; Lu Y; Li W; Tang K; Chen W; Liu Z; Qi X; Zheng J; Fassett J; Zhang Y; Xu Y
J Mol Cell Cardiol; 2019 Mar; 128():105-116. PubMed ID: 30707992
[TBL] [Abstract][Full Text] [Related]
14. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
[TBL] [Abstract][Full Text] [Related]
15. Growth Arrest-Specific 6 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy.
Zhao YF; Xu DC; Zhu GF; Zhu MY; Tang K; Li WM; Xu YW
Hypertension; 2016 Jan; 67(1):118-29. PubMed ID: 26573712
[TBL] [Abstract][Full Text] [Related]
16. Novel role for caspase-activated DNase in the regulation of pathological cardiac hypertrophy.
Gao L; Huang K; Jiang DS; Liu X; Huang D; Li H; Zhang XD; Huang K
Hypertension; 2015 Apr; 65(4):871-81. PubMed ID: 25646292
[TBL] [Abstract][Full Text] [Related]
17. Activation of Dusp14 protects against osteoclast generation and bone loss by regulating AMPKα-dependent manner.
Hong L; Ai J; Ma D
Biochem Biophys Res Commun; 2019 Nov; 519(3):445-452. PubMed ID: 31526569
[TBL] [Abstract][Full Text] [Related]
18. TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway.
Guo S; Liu Y; Gao L; Xiao F; Shen J; Xing S; Yang F; Zhang W; Shi Q; Li Y; Zhao L
Int J Biol Sci; 2020; 16(8):1335-1348. PubMed ID: 32210723
[TBL] [Abstract][Full Text] [Related]
19. Regulator of G-Protein Signaling 10 Negatively Regulates Cardiac Remodeling by Blocking Mitogen-Activated Protein Kinase-Extracellular Signal-Regulated Protein Kinase 1/2 Signaling.
Miao R; Lu Y; Xing X; Li Y; Huang Z; Zhong H; Huang Y; Chen AF; Tang X; Li H; Cai J; Yuan H
Hypertension; 2016 Jan; 67(1):86-98. PubMed ID: 26573707
[TBL] [Abstract][Full Text] [Related]
20. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
